Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
Want to see VRTX full AI Analyst Report?
VRTX Stock Chart & Stats
$441.20
$0.48(0.12%)
At close: 4:00 PM EST
$441.20
$0.48(0.12%)
Day’s Range― - ―
52-Week Range$362.50 - $507.92
Previous CloseN/A
Volume295.43K
Average Volume (3M)1.38M
Market Cap
$109.34B
Enterprise Value$102.68B
Total Cash (Recent Filing)$6.61B
Total Debt (Recent Filing)$3.88B
Price to Earnings (P/E)27.5
Beta0.56
Next Earnings
Jul 30, 2026EPS Estimate
4.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)15.47
Shares Outstanding254,359,740
10 Day Avg. Volume1,158,312
30 Day Avg. Volume1,382,499
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)6.21
Price to Sales (P/S)9.60
P/FCF Ratio36.30
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue8.53
Enterprise Value/Gross Profit9.89
Enterprise Value/Ebitda21.26
Forecast
1Y Price Target
$566.48Price Target Upside28.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering24
EPS Forecast (FY)19.15
Revenue Forecast (FY)$13.05B
Bulls Say, Bears Say
Bulls Say
Cystic Fibrosis FranchiseAnalyst notes the cystic fibrosis franchise remains dominant, with a new therapy becoming the preferred option among physicians as reimbursement improves, supporting steady prescription demand and revenue resilience.
Pipeline Diversification And Financial StrengthAnalyst highlights expanding non‑cystic fibrosis products and promising pipeline assets, backed by a strong balance sheet with no debt, which could fund development and commercialization to materially diversify revenue.
Povetacicept Clinical And Regulatory ProgressAnalyst cites strong Phase 3 interim results for povetacicept showing meaningful kidney benefit and a favorable safety profile, together with a rolling regulatory submission that could accelerate approval and broaden the company's commercial opportunity beyond cystic fibrosis.
Bears Say
Inaxaplin/APOL1 Efficacy UncertaintyAnalyst indicates that APOL1 inhibition produced less consistent benefit outside the FSGS subgroup, so expanding inaxaplin trials to a broader non‑diabetic population raises the risk that effectiveness may be limited in many patients.
Ivacaftor Label WarningAnalyst warns that label additions for ivacaftor-containing products citing neuropsychiatric symptoms are creating market noise and may exert temporary downward pressure on prescribing and the stock.
Patient Support Program ReductionAnalyst notes that scaling back the patient support program is expected to shift revenue growth into a later period, which could temporarily suppress reported sales growth.
Vertex Pharmaceuticals News
VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $362.50 and its highest was $507.92 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is $109.34B.
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 85 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on May 04, 2026. The company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.243 by $0.227.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is 4.74.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 254,359,740 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $4.47 in its last earnings report, beating expectations of $4.243. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Currently, no hedge funds are holding shares in VRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vertex Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$566.48 (28.39% Upside)
$566.48 (28.39% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 92%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 42.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.79%
12-Months-Change
Fundamentals
Return on Equity
21.79%
Trailing 12-Months
Asset Growth
15.75%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
VRTX Company Deck
VRTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a positive, execution-focused tone: strong top-line results (8% revenue growth to $2.99B), major commercial milestones (AlifTrack >$1B cumulative revenue, >1M Gernavix prescriptions, >500 KASJEVY patients initiated), and a standout Phase III interim win for povitacicept in IgAN with rapid BLA submission. At the same time, the company disclosed a program discontinuation (VX-522) due to tolerability, increased SG&A (30% YoY) tied to commercialization investments, and several important longer-term readouts (eGFR for renal programs, enaxaplin and AMPLITUDE results) remain pending. The positives — strong revenue and multiple high-impact pipeline/regulatory achievements — outweigh the challenges and near-term variability risks.View all VRTX earnings summariesVRTX Revenue Breakdown
85.93% TRIKAFTA/KAFTRIO
6.98% ALYFTREK
6.83% Other product revenues
0.26% Other revenues
VRTX Stock 12 Month Forecast
Average Price Target
$566.48
▲(28.39% Upside)
Technical Analysis
Ownership Overview
0.26% Insiders
35.42% Mutual Funds
2.94% Other Institutional Investors
32.67% Public Companies and Individual Investors